BioInvent International AB Share Price

Equities

BINV

SE0015244520

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 11:40:07 12/07/2024 BST 5-day change 1st Jan Change
36.45 SEK -0.41% Intraday chart for BioInvent International AB +12.15% +92.25%

Financials

Sales 2024 * 63.6M 6.04M 466M Sales 2025 * 753M 71.48M 5.52B Capitalization 2.41B 229M 17.65B
Net income 2024 * -353M -33.5M -2.59B Net income 2025 * 511M 48.5M 3.75B EV / Sales 2024 * 25.9 x
Net cash position 2024 * 760M 72.14M 5.57B Net cash position 2025 * 1.49B 142M 10.95B EV / Sales 2025 * 1.21 x
P/E ratio 2024 *
-9.32 x
P/E ratio 2025 *
3.76 x
Employees 109
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.64%
More Fundamentals * Assessed data
Dynamic Chart
Bioinvent International AB Presents Poster Highlighting Model-Informed Early Clinical Development of Anti-TNFR2 Agent BI-1808 At PAGE 2024 CI
BioInvent International Gains Patent for BI-1808 in China CI
Transcript : BioInvent International AB - Special Call
BioInvent Presents Promising Phase 1 Data for Bi-1206 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Solid Tumors CI
BioInvent International AB Presents Promising Clinical Efficacy and Safety for Anti-Tnfr2 Agent BI-1808 At Asco 2024 CI
Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL CI
Bioinvent International AB Resolves to Elect Laura Lassouw-Polman as New Board Member CI
BioInvent Announces Evaluating Attana Technology CI
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda MT
Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024
BioInvent International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
BioInvent International AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioInvent International AB Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607 CI
Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910 CI
More news

Latest transcript on BioInvent International AB

1 day-0.41%
1 week+12.15%
Current month-3.06%
3 months+100.05%
6 months+110.45%
Current year+92.25%
More quotes
1 week
31.45
Extreme 31.45
36.65
1 month
31.45
Extreme 31.45
39.50
Current year
15.00
Extreme 15
39.50
1 year
14.00
Extreme 14
39.50
3 years
14.00
Extreme 14
53.70
5 years
14.00
Extreme 14
63.00
10 years
14.00
Extreme 14
106.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 31/08/18
Director of Finance/CFO 61 31/12/97
Chief Operating Officer - 31/01/22
Members of the board TitleAgeSince
Director/Board Member 67 31/12/17
Chairman 66 11/05/16
Director/Board Member 55 11/05/16
More insiders
Date Price Change Volume
12/07/24 36.45 -0.41% 22 671
11/07/24 36.6 +3.39% 93,018
10/07/24 35.4 +4.73% 79,255
09/07/24 33.8 +5.30% 81,427
08/07/24 32.1 -1.23% 81,071

Delayed Quote Nasdaq Stockholm, July 12, 2024 at 11:40 am

More quotes
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
36.6 SEK
Average target price
83 SEK
Spread / Average Target
+126.78%
Consensus